
1. General Information
MABTAS RA 500 mg Injection is a prescription biological medicine containing Rituximab 500 mg. It belongs to the class of monoclonal antibodies and is manufactured/marketed by Intas Pharmaceuticals Ltd. The product is supplied as a 500 mg/50 mL intravenous infusion and requires administration by a qualified healthcare professional.
MABTAS RA is used in selected cancers and autoimmune conditions, including rheumatoid arthritis and certain B-cell malignancies. The exact indication, dose and treatment schedule depend on the patient's condition and the treating specialist's protocol.
Phoenix Exim, based in Nagpur, India, supplies pharmaceutical products for international markets including the USA, UK, Australia, Singapore, Canada, South Korea and UAE, subject to applicable regulatory and import requirements.
2. Product Information
| Product Detail | Information |
|---|---|
| Brand Name | MABTAS RA 500 mg Injection |
| Active Ingredient | Rituximab |
| Strength | 500 mg |
| Dosage Form | Concentrate/Solution for IV infusion |
| Pack Size | 500 mg/50 mL vial |
| Drug Class | Monoclonal antibody |
| Therapeutic Class | Antineoplastic / Immunomodulating agent |
| Manufacturer/Marketer | Intas Pharmaceuticals Ltd. |
| Storage | Refrigerate at 2°C–8°C; do not freeze |
| Prescription Status | Prescription medicine |
The 500 mg/50 mL presentation and rituximab composition are documented in current product references.
3. Uses of MABTAS RA 500 mg Injection
Depending on the approved indication and physician's assessment, rituximab products may be used for:
Rheumatoid arthritis (RA), generally in appropriate patients and in combination with other prescribed therapy.
Non-Hodgkin lymphoma (NHL), including certain B-cell lymphomas.
Chronic lymphocytic leukemia (CLL) in appropriate treatment regimens.
Granulomatosis with polyangiitis (GPA).
Microscopic polyangiitis (MPA).
Pemphigus vulgaris in selected patients.
The exact indication for MABTAS RA should be confirmed against the prescribing information and applicable regulatory approval in the destination country.
4. Benefits of MABTAS RA 500 mg Injection
MABTAS RA contains rituximab, a targeted monoclonal antibody that binds to the CD20 antigen on B cells. By reducing targeted B-cell populations, rituximab can help control abnormal B-cell activity in certain cancers and reduce immune-mediated inflammation in selected autoimmune diseases.
Potential therapeutic benefits include:
Helps control certain B-cell malignancies.
Can reduce disease activity in appropriately selected patients with rheumatoid arthritis.
Helps manage certain ANCA-associated vasculitides, such as GPA and MPA, when prescribed for these indications.
Provides targeted immunological action rather than conventional nonspecific chemotherapy alone.
Treatment benefits vary according to the disease, treatment regimen and individual response.
5. Side Effects of MABTAS RA 500 mg Injection
Because rituximab affects the immune system, it can cause infusion-related reactions and increase susceptibility to infections. Possible adverse effects include:
Infusion-related reactions
Fever or chills
Headache
Weakness or fatigue
Nausea
Rash or itching
Swelling
Infections
Reduced blood-cell counts
Hair loss
Some serious reactions can also occur, including severe infusion reactions, serious infections and hepatitis B reactivation. Patients receiving rituximab require appropriate medical monitoring.
6. Common Side Effects
Some commonly reported effects include:
Headache
Fever
Weakness
Nausea
Rash
Itching
Infusion-related reactions
Swelling
Increased risk of infections
Changes in blood-cell counts
Patients should promptly contact their healthcare professional if symptoms are severe, persistent or unusual.
7. How to Use MABTAS RA 500 mg Injection
MABTAS RA 500 mg Injection must not be self-administered. It is given by a doctor or trained healthcare professional as an intravenous infusion.
The dosage and infusion schedule vary substantially according to the condition being treated. Before treatment, healthcare professionals may assess blood counts, infection status and other relevant medical factors. Patients should follow the prescribed treatment schedule and should not alter the dose or infusion rate themselves.
8. How MABTAS RA 500 mg Injection Works
MABTAS RA contains rituximab, a monoclonal antibody that specifically targets CD20-positive B lymphocytes.
After binding to CD20, rituximab helps eliminate targeted B cells through immune-mediated mechanisms. This can reduce abnormal B-cell activity in certain cancers and decrease the immune response involved in some autoimmune diseases.
Because its mechanism affects immune cells, treatment can also reduce the body's ability to fight certain infections, which is why medical supervision and appropriate monitoring are important.
9. Safety Advice for MABTAS RA 500 mg Injection
Use only under the supervision of a qualified healthcare professional.
Do not self-inject or self-administer this medicine.
Tell your doctor about any active or recent infection before treatment.
Inform your doctor if you have previously had hepatitis B, as rituximab can cause hepatitis B reactivation.
Blood counts may need to be monitored during treatment.
Tell your healthcare professional about existing heart or liver problems.
Inform your doctor about all medicines, vaccines and supplements you are taking.
Discuss vaccination timing with your doctor before or during therapy.
Tell your doctor if you are pregnant, planning pregnancy or breastfeeding.
Seek urgent medical attention for severe breathing difficulty, swelling, severe rash, chest discomfort, high fever or other serious symptoms during or after infusion.
Store the product under recommended refrigerated conditions (2°C–8°C) and do not freeze.
Important: Rituximab is a specialist prescription medicine. The product should be used only for an appropriate medical indication and according to the prescribing information applicable in the patient's country.
10. Frequently Asked Questions (FAQs)
Q1. What is MABTAS RA 500 mg Injection?
MABTAS RA 500 mg Injection is a rituximab-containing prescription medicine used under specialist supervision for certain cancers and autoimmune diseases.
Q2. What is the composition of MABTAS RA 500 mg?
It contains Rituximab 500 mg, supplied as a 500 mg/50 mL presentation.
Q3. Is MABTAS RA 500 mg an injection or tablet?
It is an intravenous infusion product, not an oral tablet.
Q4. Who administers MABTAS RA?
A qualified doctor or healthcare professional administers the medicine by intravenous infusion. It should not be self-administered.
Q5. Does MABTAS RA require refrigeration?
Yes. Product references specify storage at 2°C–8°C, and it should not be frozen.
Q6. What are the major uses of rituximab?
Depending on the specific approved indication, rituximab may be used for certain B-cell cancers, rheumatoid arthritis, GPA, MPA and pemphigus vulgaris.
Q7. Can MABTAS RA cause infections?
Yes. Rituximab can affect immune function and may increase susceptibility to infections. Appropriate medical monitoring is important.
Q8. Can MABTAS RA cause an infusion reaction?
Yes. Infusion-related reactions are recognized with rituximab and are one reason the medicine is administered under medical supervision.
Q9. Is MABTAS RA 500 mg suitable for everyone?
No. Suitability depends on the medical condition, previous treatments, infection history, laboratory results and other individual factors. A specialist should determine whether rituximab is appropriate.
Q10. Can I buy or use MABTAS RA without a prescription?
It is a prescription medicine and should only be supplied and used in accordance with applicable medical and pharmaceutical regulations.
11. Substitutes for MABTAS RA 500 mg Injection
Potential same-composition rituximab 500 mg alternatives include brands such as:
Lupiximab 500 mg Injection
Unimab 500 mg Injection
Toritz RA 500 mg/50 mL Injection
Rixilta 500 mg Injection
Availability, formulation, indications and regulatory approval can differ between countries. A substitute should only be selected by a qualified healthcare professional based on the required indication and prescribing information.
12. SEO Keywords
Primary Keywords
MABTAS RA 500 mg Injection
MABTAS RA 500 mg Injection exporter
MABTAS RA 500 mg supplier India
MABTAS RA 500 mg manufacturer
Rituximab 500 mg Injection
Rituximab 500 mg exporter from India
Rituximab 500 mg supplier India
MABTAS RA Rituximab Injection
Long-Tail B2B Keywords
Buy MABTAS RA 500 mg Injection from India
MABTAS RA 500 mg Injection pharmaceutical exporter
MABTAS RA 500 mg Injection wholesale supplier India
MABTAS RA Rituximab 500 mg Injection exporter
Rituximab 500 mg Injection pharmaceutical supplier
MABTAS RA 500 mg Injection international supplier
MABTAS RA 500 mg Injection export from Nagpur India
Genuine MABTAS RA 500 mg Injection supplier from India
MABTAS RA 500 mg Injection for international pharmaceutical supply
Rituximab 500 mg Injection exporter from Nagpur India
Country-Focused Keywords
MABTAS RA 500 mg Injection exporter to USA
MABTAS RA 500 mg Injection supplier to UK
MABTAS RA 500 mg Injection exporter to Australia
MABTAS RA 500 mg Injection supplier to Singapore
MABTAS RA 500 mg Injection exporter to Canada
MABTAS RA 500 mg Injection supplier to South Korea
MABTAS RA 500 mg Injection exporter to UAE
Rituximab 500 mg Injection exporter from India to USA
Rituximab 500 mg Injection supplier from India to UK
Rituximab 500 mg pharmaceutical exporter from India
Keywords







